Table 1. Clinical characteristics of the patients included in the study according to STOP-Bang scores (N = 435).a .
| Characteristic | STOP-Bang score | p* | ||
|---|---|---|---|---|
| 0-2 | ≥ 3 | ≥ 5 | ||
| (n = 83) | (n = 352) | (n = 182) | ||
| Age, years | 56.61 ± 18.74 | 62.01 ± 16.57 | 62.55 ± 15.04 | 0.01 |
| Age ≥ 65 years | 38.5% | 47.4% | 65.1% | 0.12 |
| Male | 44.57% | 55.68% | 60.43% | 0.01 |
| BMI, kg/m2 | 30.72 ± 5.73 | 33.93 ± 6.58 | 35.78 ± 6.96 | < 0.01 |
| BMI ≥ 35 kg/m2 | 9.4% | 12.5% | 14.1% | < 0.01 |
| ASCVD, % | 10.1 ± 11.2 | 22.6 ± 16.3 | 24.6 ± 15.8 | < 0.01 |
| Former/current smoking | 38.4% | 52.3% | 59.1% | < 0.01 |
| Hypertension | 19.2% | 73.2% | 84.0% | < 0.01 |
| Diabetes mellitus | 14.4% | 43.7% | 50.0% | < 0.01 |
| Dyslipidemia | 37.3% | 59.3% | 59.3% | 0.01 |
| Hypertriglyceridemia | 41.9% | 33.9% | 34.3% | |
| High LDL | 38.7% | 28.7% | 24.0% | |
| Mixed dyslipidemia | 19.3% | 37.3% | 41.6% | |
| Medication | ||||
| Lipid-lowering | 31.6% | 48.3% | 43.5% | < 0.01 |
| Antidiabetic | 9.2% | 39.4% | 48.1% | < 0.01 |
| Anticoagulant | 16.2% | 52.0% | 71.5% | < 0.01 |
| Antihypertensive | 15.2% | 68.7% | 75.4% | < 0.01 |
| Reason for admission | ||||
| Decompensated HF | 12.0% | 13.0% | 10.9% | 0.47 |
| AF | 4.6% | 34.0% | 1.0% | 0.17 |
| CHD | 15.6% | 15.9% | 13.7% | 0.40 |
| AMI | 1.2% | 2.5% | 37.9% | 0.29 |
ASCVD: American College of Cardiology/American Heart Association Atherosclerotic Cardiovascular Disease risk score; HF: heart failure; AF: atrial fibrillation; CHD: coronary heart disease; and AMI: acute myocardial infarction; aValues expressed as mean ± SD, except where otherwise indicated. *In comparison with the STOP-Bang score 0-2 group.